Research programme: sodium channel antagonists - Vernalis
Latest Information Update: 09 Apr 2021
At a glance
- Originator Vernalis
- Class
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Neuropathic pain; Stroke
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom
- 05 Oct 2004 This programme is still in active development for CNS disorders